Full Member
Dr Rosie McNeil
Membership since:
2008
Field of activity:
Other Memberships/Affiliations
American Association of Anatomists -AAA
Anatomical society of Southern Africa-ASSA
American Association of clinical Anatomists- AACA
Neuroscience Society of Nigeria
Degrees:
2018
Doctorate
Structural, Cell and Molecular Biology
1999
Master
Structural, Cell and Molecular Biology
1986
Undergraduate
Medical and Health Sciences incl Neurosciences
Publications resulting from Research
ROSIE THECLA MCNEIL, MARGOT JILL HOSIE AND CLEMENT BRIAN PENNY (2017). Developmental angiogenesis: expression of vascular endothelial growth factor (VEGF) in the developing avian lung. Int J Res Med and Health Sci 13(1): 1 -7
ROSIE T MCNEIL, CLEMENT B PENNY, AND MARGOT J HOSIE (2017). Antiretroviral therapy and HIV-associated cancers: anti-angiogenic effect of Efavirenz on chick chorioallantoic membrane (CAM). Trop J Pharm Res 16 (11): 2741-2747
Rosie Thecla McNeil, Margot Jill Hosie and Clement Brian Penny (2017). Perineural angiogenesis: expression of Vascular endothelial growth factor (VEGF) in the developing spinal cord. FASEB Abstract 2016
Rosie Thecla McNeil, Margot Jill Hosie and Clement Brian Penny (2017). Developmental angiogenesis: expression of Vascular endothelial growth factor (VEGF) in the developing kidney. FASEB Abstract 2017
ROSIE T MCNEIL, CLEMENT B PENNY, AND MARGOT J HOSIE (2017). Antiretroviral therapy and HIV-associated cancers: anti-angiogenic effect of Efavirenz on chick chorioallantoic membrane (CAM). Trop J Pharm Res 16 (11): 2741-2747
Rosie Thecla McNeil, Margot Jill Hosie and Clement Brian Penny (2017). Perineural angiogenesis: expression of Vascular endothelial growth factor (VEGF) in the developing spinal cord. FASEB Abstract 2016
Rosie Thecla McNeil, Margot Jill Hosie and Clement Brian Penny (2017). Developmental angiogenesis: expression of Vascular endothelial growth factor (VEGF) in the developing kidney. FASEB Abstract 2017
“Cancer Free World – Possible or Not”
2025
London
Avoiding Drug overload and improving patient compliance by exploring the anti-cancer properties of ARDS: Efavirenz. Accepted.
“3rd Edition of International Cancer Conference” (ICC 2019) in September 23-25, 2019 at London.
2025
London